New drugs and combinations for the treatment of soft-tissue sarcoma: A review

Cancer Management and Research

Volumn 4, Issue 1, 2012, Pages 397-411

  Somaiah, Neeta ^a   von Mehren, Margaret ^b  

^a UNIVERSITY OF TEXAS   (United States)

^b FOX CHASE CANCER CENTER   (United States)

Author keywords

Clinical trials; Palifosfamide; Pazopanib; Soft tissue sarcoma; Trabectedin

Indexed keywords

ADZ 2171; ANTINEOPLASTIC AGENT; BEVACIZUMAB; BRIVANIB; CABOZANTINIB; CEDIRANIB; CIXUTUMUMAB; CRIZOTINIB; CYCLOPHOSPHAMIDE; DACARBAZINE; DOCETAXEL; DOXORUBICIN; ERIBULIN; EVEROLIMUS; FIGITUMUMAB; GEMCITABINE; IFOSFAMIDE; IMATINIB; PACLITAXEL; PALIFOSFAMIDE; PAZOPANIB; PLACEBO; RAPAMYCIN; RIDAFOROLIMUS; SORAFENIB; SUNITINIB; TEMOZOLOMIDE; TEMSIROLIMUS; TH 302; TORICEL; TRABECTEDIN; UNCLASSIFIED DRUG;

ABDOMINAL PAIN; ADVANCED CANCER; ALVEOLAR SOFT PART SARCOMA; ANEMIA; ANGIOMYOLIPOMA; ANGIOSARCOMA; ANOREXIA; ANTINEOPLASTIC ACTIVITY; ARTHRALGIA; ASTHENIA; BLEEDING; BLOOD TOXICITY; BREAST CANCER; CANCER COMBINATION CHEMOTHERAPY; CANCER PAIN; CANCER PROGNOSIS; CANCER SURVIVAL; CARCINOGENESIS; CENTRAL NERVOUS SYSTEM DISEASE; CLEAR CELL SARCOMA; CLINICAL EVALUATION; COLORECTAL CANCER; CONGESTIVE HEART FAILURE; CONSTIPATION; CONTINUOUS INFUSION; COUGHING; DEEP VEIN THROMBOSIS; DESMOPLASTIC SMALL ROUND CELL TUMOR; DIARRHEA; DISEASE FREE SURVIVAL; DRUG EFFICACY; DRUG ERUPTION; DRUG FEVER; DRUG INDUCED HEADACHE; DRUG RESPONSE; DRUG TOLERABILITY; DYSGEUSIA; ELECTROLYTE DISTURBANCE; EWING SARCOMA; FATIGUE; FEBRILE NEUTROPENIA; FIBROSARCOMA; FULMINANT HEPATIC FAILURE; GLIOBLASTOMA; HAIR COLOR; HAND FOOT SYNDROME; HEART EJECTION FRACTION; HEART LEFT VENTRICLE EJECTION FRACTION; HEMANGIOENDOTHELIOMA; HEMANGIOPERICYTOMA; HUMAN; HYPERBILIRUBINEMIA; HYPERGLYCEMIA; HYPERTENSION; HYPERTRANSAMINASEMIA; INTESTINE PERFORATION; KIDNEY CANCER; KIDNEY CARCINOMA; LEIOMYOSARCOMA; LEUKOPENIA; LIPOSARCOMA; LIVER CELL CARCINOMA; LIVER TOXICITY; LUNG NON SMALL CELL CANCER; LYMPHANGIOLEIOMYOMATOSIS; LYMPHOCYTOPENIA; METASTASIS; MONOTHERAPY; MUCOSA INFLAMMATION; MULTIPLE CYCLE TREATMENT; MYXOSARCOMA; NAUSEA; NEPHROTOXICITY; NEUTROPENIA; OSTEOSARCOMA; OVARY CANCER; OVERALL SURVIVAL; PAIN; PERIVASCULAR EPITHELIOID CELL TUMOR; PNEUMOTHORAX; PROGRESSION FREE SURVIVAL; PROTEINURIA; REVIEW; RHABDOMYOLYSIS; RHABDOMYOSARCOMA; SARCOMA; SENSORY NEUROPATHY; SIDE EFFECT; SKIN CANCER; SKIN DISEASE; SKIN TOXICITY; SKIN ULCER; SOFT TISSUE SARCOMA; SOLITARY FIBROUS TUMOR; STOMATITIS; SYNOVIAL SARCOMA; THROMBOCYTOPENIA; TREATMENT DURATION; TUBEROUS SCLEROSIS; UTERUS MYOMA; UTERUS SARCOMA; VEIN THROMBOSIS; VOMITING;

EID: 84871636601     PISSN: None     EISSN: 11791322     Source Type: Journal    
DOI: 10.2147/CMAR.S23257     Document Type: Review

References (105)

1. Jemal A, Bray F, Center MM, Ferlay J, Ward E, Forman D. Global cancer statistics. CA Cancer J Clin. 2011;61(2):69-90.
2. Stojadinovic A, Leung DH, Hoos A, Jaques DP, Lewis JJ, Brennan MF. Analysis of the prognostic significance of microscopic margins in 2,084 localized primary adult soft tissue sarcomas. Ann Surg. 2002;235(3): 424-434.
3. O'Sullivan B, Davis AM, Turcotte R., et al. Preoperative versus postoperative radiotherapy in soft-tissue sarcoma of the limbs: a randomised trial. Lancet. 2002;359(9325):2235-2241.
4. [No authors listed]. Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet. 1997;350(9092):1647-1654.
5. Pervaiz N, Colterjohn N, Farrokhyar F, Tozer R, Figueredo A, Ghert M. A systematic meta-analysis of randomized controlled trials of adjuvant chemotherapy for localized resectable soft-tissue sarcoma. Cancer. 2008;113(3):573-581.
6. Woll PJ, Van Glabbeke M, Hohenberger P., et al. Adjuvant chemotherapy (CT) with doxorubicin and ifosfamide in resected soft tissue sarcoma (STS): interim analysis of a randomised phase III trial. J Clin Oncol. 2007;25(Suppl 18):10008.
7. O'Connor JM, Chacón M, Petracci FE, Chacón RD. Adjuvant chemotherapy in soft tissue sarcoma (STS): a meta-analysis of published data. J Clin Oncol. 2008;26 Suppl:10526.
8. Bramwell V, Rouesse J, Steward W., et al. Adjuvant CYVADIC chemotherapy for adult soft tissue sarcoma - reduced local recurrence but no improvement in survival: a study of the European Organization for Research and Treatment of Cancer Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 1994;12(6):1137-1149.
9. Le Cesne A, Van Glabbeke M, Woll PJ., et al. The end of adjuvant chemotherapy (adCT) era with doxorubicin-based regimen in resected high-grade soft tissue sarcoma (STS): pooled analysis of the two STBSG-EORTC phase III clinical trials. J Clin Oncol. 2008;26 Suppl: 10525.
10. Ferrari A, Gronchi A, Casanova M., et al. Synovial sarcoma: a retrospective analysis of 271 patients of all ages treated at a single institution. Cancer. 2004;101(3):627-634.
11. Eilber FC, Eilber FR, Eckardt J., et al. The impact of chemotherapy on the survival of patients with high-grade primary extremity liposarcoma. Ann Surg. 2004;240(4):686-695; discussion 695-687.
12. Verweij J, Mouridsen HT, Nielssen OS., et al. The present state of the art in chemotherapy for soft tissue sarcomas in adults: the EORTC point of view. Crit Rev Oncol Hematol. 1995;20(3):193-201.
13. Hensley ML, Maki R, Venkatraman E., et al. Gemcitabine and docetaxel in patients with unresectable leiomyosarcoma: results of a phase II trial. J Clin Oncol. 2002;20(12):2824-2831.
14. Hensley ML, Blessing JA, Degeest K, Abulafia O, Rose PG, Homesley HD. Fixed-dose rate gemcitabine plus docetaxel as second-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2008;109(3):323-328.
15. Hensley ML, Blessing JA, Mannel R, Rose PG. Fixed-dose rate gemcitabine plus docetaxel as first-line therapy for metastatic uterine leiomyosarcoma: a Gynecologic Oncology Group phase II trial. Gynecol Oncol. 2008;109(3):329-334.
16. Maki RG, Wathen JK, Patel SR., et al. Randomized phase II study of gemcitabine and docetaxel compared with gemcitabine alone in patients with metastatic soft tissue sarcomas: results of sarcoma alliance for research through collaboration study 002 [corrected]. J Clin Oncol. 2007;25(19):2755-2763.
17. Bay JO, Ray-Coquard I, Fayette J., et al. Docetaxel and gemcitabine combination in 133 advanced soft-tissue sarcomas: a retrospective analysis. Int J Cancer. 2006;119(3):706-711.
18. Sleijfer S, Ouali M, van Glabbeke M., et al. Prognostic and predictive factors for outcome to first-line ifosfamide-containing chemotherapy for adult patients with advanced soft tissue sarcomas: an exploratory, retrospective analysis on large series from the European Organization for Research and Treatment of Cancer-Soft Tissue and Bone Sarcoma Group (EORTC-STBSG). Eur J Cancer. 2010;46(1):72-83.
19. Fury MG, Antonescu CR, Van Zee KJ, Brennan MF, Maki RG. A 14-year retrospective review of angiosarcoma: clinical characteristics, prognostic factors, and treatment outcomes with surgery and chemotherapy. Cancer J. 2005;11(3):241-247.
20. Scurr M. Histology-driven chemotherapy in soft tissue sarcomas. Curr Treat Options Oncol. 2011;12(1):32-45.
21. Antman K, Crowley J, Balcerzak SP., et al. An intergroup phase III randomized study of doxorubicin and dacarbazine with or without ifosfamide and mesna in advanced soft tissue and bone sarcomas. J Clin Oncol. 1993;11(7):1276-1285.
22. Bramwell VH, Anderson D, Charette ML. Doxorubicin-based chemotherapy for the palliative treatment of adult patients with locally advanced or metastatic soft-tissue sarcoma: a meta-analysis and clinical practice guideline. Sarcoma. 2000;4(3):103-112.
23. Jelic S, Kovcin V, Milanovic N., et al. Randomised study of high-dose epirubicin versus high-dose epirubicin-cisplatin chemotherapy for advanced soft tissue sarcoma. Eur J Cancer. 1997;33(2):220-225.
24. Le Cesne A, Judson I, Crowther D., et al. Randomized phase III study comparing conventional-dose doxorubicin plus ifosfamide versus high-dose doxorubicin plus ifosfamide plus recombinant human granulocyte-macrophage colony-stimulating factor in advanced soft tissue sarcomas: a trial of the European Organization for Research and Treatment of Cancer/Soft Tissue and Bone Sarcoma Group. J Clin Oncol. 2000;18(14):2676-2684.
25. Hartmann JT, Oechsle K, Huober J., et al. An open label, non-comparative phase II study of gemcitabine as salvage treatment for patients with pretreated adult type soft tissue sarcoma. Invest New Drugs. 2006;24(3):249-253.
26. Pazdur R, Samson MK, Baker LH. Fludarabine phosphate. Phase II evaluation in advanced soft-tissue sarcomas. Am J Clin Oncol. 1987; 10(4):341-343.
27. Reichardt P, Oechsle K, Pink D., et al. An open label, non-comparative phase II study of topotecan as salvage treatment for patients with soft tissue sarcoma. Invest New Drugs. 2003;21(4):481-486.
28. Rose PG, Blessing JA, Soper JT, Barter JF. Prolonged oral etoposide in recurrent or advanced leiomyosarcoma of the uterus: a gynecologic oncology group study. Gynecol Oncol. 1998;70(2):267-271.
29. Woll PJ, Judson I, Lee SM., et al. Temozolomide in adult patients with advanced soft tissue sarcoma: a phase II study of the EORTC Soft Tissue and Bone Sarcoma Group. Eur J Cancer. 1999;35(3):410-412.
30. Van Glabbeke M, Verweij J, Judson I, Nielsen OS. Progression-free rate as the principal end-point for phase II trials in soft-tissue sarcomas. Eur J Cancer. 2002;38(4):543-549.
31. David-Cordonnier MH, Gajate C, Olmea O., et al. DNA and non-DNA targets in the mechanism of action of the antitumor drug trabectedin. Chem Biol. 2005;12(11):1201-1210.
32. Takebayashi Y, Pourquier P, Zimonjic DB., et al. Antiproliferative activity of ecteinascidin 743 is dependent upon transcription-coupled nucleotide-excision repair. Nat Med. 2001;7(8):961-966.
33. Friedman D, Hu Z, Kolb EA, Gorfajn B, Scotto KW. Ecteinascidin-743inhibits activated but not constitutive transcription. Cancer Res. 2002;62(12):3377-3381.
34. Takebayashi Y, Goldwasser F, Urasaki Y, Kohlhagen G, Pommier Y. Ecteinascidin 743induces protein-linked DNA breaks in human colon carcinoma HCT116cells and is cytotoxic independently of topoisomerase I expression. Clin Cancer Res. 2001;7(1):185-191.
35. Herrero AB, Martin-Castellanos C, Marco E, Gago F, Moreno S. Cross-talk between nucleotide excision and homologous recombination DNA repair pathways in the mechanism of action of antitumor trabectedin. Cancer Res. 2006;66(16):8155-8162.
36. Delaloge S, Yovine A, Taamma A., et al. Ecteinascidin-743: a marine-derived compound in advanced, pretreated sarcoma patients - preliminary evidence of activity. J Clin Oncol. 2001;19(5):1248-1255.
37. Yovine A, Riofrio M, Blay JY., et al. Phase II study of ecteinascidin-743in advanced pretreated soft tissue sarcoma patients. J Clin Oncol. 2004;22(5):890-899.
38. Garcia-Carbonero R, Supko JG, Manola J., et al. Phase II and pharmacokinetic study of ecteinascidin 743in patients with progressive sarcomas of soft tissues refractory to chemotherapy. J Clin Oncol. 2004;22(8):1480-1490.
39. Le Cesne A, Blay JY, Judson I., et al. Phase II study of ET-743in advanced soft tissue sarcomas: a European Organisation for the Research and Treatment of Cancer (EORTC) soft tissue and bone sarcoma group trial. J Clin Oncol. 2005;23(3):576-584.
40. Huygh G, Clement PM, Dumez H., et al. Ecteinascidin-743: evidence of activity in advanced, pretreated soft tissue and bone sarcoma patients. Sarcoma. 2006;2006:56282.
41. Garcia-Carbonero R, Supko JG, Maki RG., et al. Ecteinascidin-743 (ET-743) for chemotherapy-naive patients with advanced soft tissue sarcomas: multicenter phase II and pharmacokinetic study. J Clin Oncol. 2005;23(24):5484-5492.
42. Gronchi A, Bui BN, Bonvalot S., et al. Phase II clinical trial of neoadjuvant trabectedin in patients with advanced localized myxoid liposarcoma. Ann Oncol. 2012;23(3):771-776.
43. Demetri GD, Chawla SP, von Mehren M., et al. Efficacy and safety of trabectedin in patients with advanced or metastatic liposarcoma or leiomyosarcoma after failure of prior anthracyclines and ifosfamide: results of a randomized phase II study of two different schedules. J Clin Oncol. 2009;27(25):4188-4196.
44. Gomez J, Lázaro LL, Guzman C, Gonzalez A, Misset J, Twelves C. Identification of biochemical parameters that predict the onset of severe toxicities in patients treated with ET-743. Proc Am Soc Clin Oncol. 2000;19:727.
45. Taamma A, Misset JL, Riofrio M., et al. Phase I and pharmacokinetic study of ecteinascidin-743, a new marine compound, administered as a 24-hour continuous infusion in patients with solid tumors. J Clin Oncol. 2001;19(5):1256-1265.
46. Grosso F, Dileo P, Sanfilippo R., et al. Steroid premedication markedly reduces liver and bone marrow toxicity of trabectedin in advanced sarcoma. Eur J Cancer. 2006;42(10):1484-1490.
47. Hingorani P, Zhang W, Piperdi S., et al. Preclinical activity of palifosfamide lysine (ZIO-201) in pediatric sarcomas including oxazaphosphorine-resistant osteosarcoma. Cancer Chemother Pharmacol. 2009;64(4): 733-740.
48. Jones B, Komarnitsky P, Miller GT, Amedio J, Wallner BP. Anticancer activity of stabilized palifosfamide in vivo: schedule effects, oral bioavailability, and enhanced activity with docetaxel and doxorubicin. Anticancer Drugs. 2012;23(2):173-184.
49. Chugh R, Chawla S, Benjamin R, Heaton J, Stevens J, Schwartz B. Phase I/II study of ZIO-201in advanced sarcoma. ESMO 32nd Congress; July 5-8, 2007; Lugano, Switzerland.
50. Chawla S, Chua V, Abbadessa G, LoBue L, Lewis J. A study of palifosfamide in combination with doxorubicin: safety and preliminary efficacy. Connective Tissue Oncology Society 14th Annual Meeting; November 13-15, 2008; London, UK.
51. Verschraegen CF, Mita MM, Ryan CW., et al. A phase II, randomized, controlled trial of palifosfamide plus doxorubicin versus doxorubicin in patients with soft tissue sarcoma (PICASSO). J Clin Oncol. 2010;28(Suppl 15):10004.
52. Duan JX, Jiao H, Kaizerman J., et al. Potent and highly selective hypoxia-activated achiral phosphoramidate mustards as anticancer drugs. J Med Chem. 2008;51(8):2412-2420.
53. Weiss GJ, Infante JR, Chiorean EG., et al. Phase 1 study of the safety, tolerability, and pharmacokinetics of TH-302, a hypoxia-activated prodrug, in patients with advanced solid malignancies. Clin Cancer Res. 2011;17(9):2997-3004.
54. Ganjoo KN, Cranmer LD, Butrynski JE., et al. A phase I study of the safety and pharmacokinetics of the hypoxia-activated prodrug TH-302in combination with doxorubicin in patients with advanced soft tissue sarcoma. Oncology. 2011;80(1-2):50-56.
55. Chawla SP, Adkins D, Reed D., et al. TH-302in combination with doxorubicin in patients with first line advanced soft tissue sarcoma previously untreated with chemotherapy. 2011 Combined Meeting of the Connective Tissue Oncology Society and the Musculoskeletal Tumor Society. October 26-29, 2011; Chicago, US.
56. Schoffski P, Ray-Coquard IL, Cioffi A., et al. Activity of eribulin mesylate in patients with soft-tissue sarcoma: a phase 2study in four independent histological subtypes. Lancet Oncol. 2011;12(11):1045-1052.
57. Heymach JV. Angiogenesis and antiangiogenic approaches to sarcomas. Curr Opin Oncol. 2001;13(4):261-269.
58. Yoon SS, Segal NH, Olshen AB, Brennan MF, Singer S. Circulating angiogenic factor levels correlate with extent of disease and risk of recurrence in patients with soft tissue sarcoma. Ann Oncol. 2004;15(8): 1261-1266.
59. Sleijfer S, Ray-Coquard I, Papai Z., et al. Pazopanib, a multikinase angiogenesis inhibitor, in patients with relapsed or refractory advanced soft tissue sarcoma: a phase II study from the European organisation for research and treatment of cancer-soft tissue and bone sarcoma group (EORTC study 62043). J Clin Oncol. 2009;27(19):3126-3132.
60. van der Graaf WT, Blay JY, Chawla SP., et al. Pazopanib for metastatic soft-tissue sarcoma (PALETTE): a randomised, double-blind, placebo-controlled phase 3 trial. Lancet. 2012;379(9829):1879-1886.
61. Weiner TM, Liu ET, Craven RJ, Cance WG. Expression of growth factor receptors, the focal adhesion kinase, and other tyrosine kinases in human soft tissue tumors. Ann Surg Oncol. 1994;1(1):18-27.
62. Franklin WA, Christison WH, Colley M, Montag AG, Stephens JK, Hart CE. In situ distribution of the beta-subunit of platelet-derived growth factor receptor in nonneoplastic tissue and in soft tissue tumors. Cancer Res. 1990;50(19):6344-6348.
63. Strumberg D, Richly H, Hilger RA., et al. Phase I clinical and pharmacokinetic study of the novel Raf kinase and vascular endothelial growth factor receptor inhibitor BAY 43-9006in patients with advanced refractory solid tumors. J Clin Oncol. 2005;23(5):965-972.
64. Maki RG, D'Adamo DR, Keohan ML., et al. Phase II study of sorafenib in patients with metastatic or recurrent sarcomas. J Clin Oncol. 2009; 27(19):3133-3140.
65. von Mehren M, Rankin C, Goldblum JR., et al. Phase 2 Southwest Oncology Group-directed intergroup trial (S0505) of sorafenib in advanced soft tissue sarcomas. Cancer. 2012;118(3):770-776.
66. Ray-Coquard I, Italiano A, Bompas E., et al. Sorafenib for patients with advanced angiosarcoma: a phase II trial from the French Sarcoma Group (GSF/GETO). Oncologist. 2012;17(2):260-266.
67. Gounder MM, Lefkowitz RA, Keohan ML., et al. Activity of sorafenib against desmoid tumor/deep fibromatosis. Clin Cancer Res. 2011; 17(12):4082-4090.
68. Chugh R, Wathen JK, Patel SR., et al. Efficacy of imatinib in aggressive fibromatosis: Results of a phase II multicenter Sarcoma Alliance for Research through Collaboration (SARC) trial. Clin Cancer Res. 2010;16(19):4884-4891.
69. George S, Blay JY, Casali PG., et al. Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure. Eur J Cancer. 2009;45(11):1959-1968.
70. George S, Merriam P, Maki RG., et al. Multicenter phase II trial of sunitinib in the treatment of nongastrointestinal stromal tumor sarcomas. J Clin Oncol. 2009;27(19):3154-3160.
71. Stacchiotti S, Negri T, Libertini M., et al. Sunitinib malate in solitary fibrous tumor (SFT). Ann Oncol. Epub June 17, 2012.
72. Hensley ML, Sill MW, Scribner DR Jr., et al. Sunitinib malate in the treatment of recurrent or persistent uterine leiomyosarcoma: a Gynecologic Oncology Group phase II study. Gynecol Oncol. 2009;115(3): 460-465.
73. Schwartz GK, Ratain MJ, Undevia SD., et al. Brivanib (BMS-582664) in advanced soft-tissue sarcoma (STS): biomarker and subset results of a phase II randomized discontinuation tria. J Clin Oncol. 2011;29 Suppl:10000.
74. Gardner K, Leahy M, Barquin E., et al. Activity of cediranib, a highly potent and selective VEGF signaling inhibitor, in alveolar soft part sarcoma. J Clin Oncol. 2009;27 Suppl 15:10523.
75. Kummar S, Monks A, Ivy SP., et al. An evaluation of cediranib as a new agent for alveolar soft part sarcoma (ASPS). J Clin Oncol. 2011;29 Suppl:10001.
76. Agulnik M, Von Mehren M, Jovanovic B, Brockstein B, Benjamin RS, Evens AM. An open-label multicenter phase II study of bevacizumab for the treatment of angiosarcoma. J Clin Oncol. 2009;27 Suppl 15:10522.
77. Fuller CK, Charlson JA, Dankle SK, Russell TJ. Dramatic improvement of inoperable angiosarcoma with combination paclitaxel and bevacizumab chemotherapy. J Am Acad Dermatol. 2010;63(4):e83-e84.
78. Rosen A, Thimon S, Ternant D, Machet MC, Paintaud G, Machet L. Partial response to bevacizumab of an extensive cutaneous angiosarcoma of the face. Br J Dermatol. 2010;163(1):225-227.
79. D'Adamo DR, Anderson SE, Albritton K., et al. Phase II study of doxorubicin and bevacizumab for patients with metastatic soft-tissue sarcomas. J Clin Oncol. 2005;23(28):7135-7142.
80. Verschraegen CF, Arias-Pulido H, Lee SJ., et al. Phase IB study of the combination of docetaxel, gemcitabine, and bevacizumab in patients with advanced or recurrent soft tissue sarcoma: the Axtell regimen. Ann Oncol. 2012;23(3):785-790.
81. Park MS, Patel SR, Ludwig JA., et al. Activity of temozolomide and bevacizumab in the treatment of locally advanced, recurrent, and metastatic hemangiopericytoma and malignant solitary fibrous tumor. Cancer. 2011;117(21):4939-4947.
82. Choi H, Charnsangavej C, Faria SC., et al. Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria. J Clin Oncol. 2007;25(13):1753-1759.
83. Rikhof B, de Jong S, Suurmeijer AJ, Meijer C, van der Graaf WT. The insulin-like growth factor system and sarcomas. J Pathol. 2009;217(4): 469-482.
84. Prieur A, Tirode F, Cohen P, Delattre O. EWS/FLI-1silencing and gene profiling of Ewing cells reveal downstream oncogenic pathways and a crucial role for repression of insulin-like growth factor binding protein 3. Mol Cell Biol. 2004;24(16):7275-7283.
85. Malempati S, Weigel B, Ingle AM., et al. Phase I/II trial and pharmacokinetic study of cixutumumab in pediatric patients with refractory solid tumors and Ewing sarcoma: a report from the Children's Oncology Group. J Clin Oncol. 2012;30(3):256-262.
86. Tolcher AW, Sarantopoulos J, Patnaik A., et al. Phase I, pharmacokinetic, and pharmacodynamic study of AMG 479, a fully human monoclonal antibody to insulin-like growth factor receptor 1. J Clin Oncol. 2009;27(34):5800-5807.
87. Schoffski P, Adkins D, Blay J., et al. Phase II trial of anti-IGF-IR antibody cixutumumab in patients with advanced or metastatic soft-tissue sarcoma and Ewing family of tumors. J Clin Oncol. 2011;29 Suppl 15: 10004.
88. Kurmasheva RT, Dudkin L, Billups C, Debelenko LV, Morton CL, Houghton PJ. The insulin-like growth factor-1 receptor-targeting antibody, CP-751,871, suppresses tumor-derived VEGF and synergizes with rapamycin in models of childhood sarcoma. Cancer Res. 2009;69(19):7662-7671.
89. Naing A, LoRusso P, Fu S., et al. Insulin growth factor-receptor (IGF-1R) antibody cixutumumab combined with the mTOR inhibitor temsirolimus in patients with refractory Ewing's sarcoma family tumors. Clin Cancer Res. 2012;18(9):2625-2631.
90. Schwartz GK TW, Qin L., et al. A phase II multicenter study of the IGF-1 receptor antibody cixutumumab (A12) and the mTOR inhibitor temsirolimus (TEM) in patients (pts) with refractory IGF-1R positive (+) and negative (-) bone and soft tissue sarcomas (STS). J Clin Oncol. 2012;30 Suppl:10003.
91. Chugh R, Griffith KA, Brockstein B, Undevia SD, Stadler WM, Schuetze S. Phase I study of doxorubicin (D) plus anti-insulin-like growth factor 1 receptor (IGF-1R) antibody cixutumumab (IMC-A12) in advanced soft tissue sarcoma (STS). J Clin Oncol. 2012;30 Suppl: 10028.
92. Schmelzle T, Hall MN. TOR, a central controller of cell growth. Cell. 2000;103(2):253-262.
93. Brown EJ, Schreiber SL. A signaling pathway to translational control. Cell. 1996;86(4):517-520.
94. Chawla SP, Staddon AP, Baker LH., et al. Phase II study of the mammalian target of rapamycin inhibitor ridaforolimus in patients with advanced bone and soft tissue sarcomas. J Clin Oncol. 2012;30(1):78-84.
95. Okuno S, Bailey H, Mahoney MR., et al. A phase 2study of temsirolimus (CCI-779) in patients with soft tissue sarcomas: a study of the Mayo phase 2 consortium (P2C). Cancer. 2011;117(15):3468-3475.
96. Quek R, Wang Q, Morgan JA., et al. Combination mTOR and IGF-1R inhibition: phase I trial of everolimus and figitumumab in patients with advanced sarcomas and other solid tumors. Clin Cancer Res. 2011; 17(4):871-879.
97. Schuetze SM, Baker LH, Maki RG. Sirolimus reduced tumor-related morbidity and resulted in biochemical and radiographic response in patients with progressive sarcoma. J Clin Oncol. 2006;24 Suppl 18: Abstr 9503.
98. Schuetze S, Zhao L, Chugh R., et al. Results of a phase II trial of sirolimus (S) and cyclophosphamide (C) in advanced sarcoma. J Clin Oncol. 2011;29 Suppl:10003.
99. Wagner AJ, Malinowska-Kolodziej I, Morgan JA., et al. Clinical activity of mTOR inhibition with sirolimus in malignant perivascular epithelioid cell tumors: targeting the pathogenic activation of mTORC1in tumors. J Clin Oncol. 2010;28(5):835-840.
100. Italiano A, Delcambre C, Hostein I., et al. Treatment with the mTOR inhibitor temsirolimus in patients with malignant PEComa. Ann Oncol. 2010;21(5):1135-1137.
101. Kuhnen C, Muehlberger T, Honsel M, Tolnay E, Steinau HU, Muller KM. Impact of c-Met expression on angiogenesis in soft tissue sarcomas: correlation to microvessel-density. J Cancer Res Clin Oncol. 2003;129(7):415-422.
102. Oda Y, Sakamoto A, Saito T, Kinukawa N, Iwamoto Y, Tsuneyoshi M. Expression of hepatocyte growth factor (HGF)/scatter factor and its receptor c-MET correlates with poor prognosis in synovial sarcoma. Hum Pathol. 2000;31(2):185-192.
103. Kurzrock R, Sherman SI, Ball DW., et al. Activity of XL184 (Cabozantinib), an oral tyrosine kinase inhibitor, in patients with medullary thyroid cancer. J Clin Oncol. 2011;29(19):2660-2666.
104. Butrynski JE, D'Adamo DR, Hornick JL., et al. Crizotinib in ALK-rearranged inflammatory myofibroblastic tumor. N Engl J Med. 2010; 363(18):1727-1733.
105. Singer S, Socci ND, Ambrosini G., et al. Gene expression profiling of liposarcoma identifies distinct biological types/subtypes and potential therapeutic targets in well-differentiated and dedifferentiated liposarcoma. Cancer Res. 2007;67(14):6626-6636.